1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
UnicoCell Biomed Co., Ltd.

UnicoCell Biomed Co., Ltd.

TTWSE:6794
68.60
TWD
-0.40
(-0.58%)
5.06BMarket Cap
Nov 06Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.18
0.34
0.51
0.11
0.22
0.35
0.46
0.56
0.49
- -
Basic EPS, GAAP
- -
-2.49
-3.3
-3.05
-2.27
-2.2
-1.56
-1.62
-1.89
- -
Free Cash Flow per Basic Share
-1.31
-4.2
-4.18
-4.16
-2.26
-1.88
-1.52
-1.17
-1.59
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
3.63
7.21
7.78
9.07
6.91
7.88
10.71
11.72
13.6
12.86
Tangible Book Value per Share
3.63
7.17
7.74
9.05
6.9
7.87
10.71
11.71
13.6
12.86
Basic Weighted Avg Shares
34
16
31
36
38
41
54
57
61
63
Sales/Revenue/Turnover
6
5
16
4
8
14
25
32
30
- -
Operating Margin (%)
-739.17
-1,256.52
-642.23
-2,796.43
-1,068.08
-639.78
-391.55
-322.82
-432.39
- -
Depreciation Expense
5
5
21
24
26
24
26
28
21
- -
Net Income, GAAP
- -
-41
-101
-109
-86
-91
-84
-93
-115
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-737.58
-641.41
-2,742.57
-1,056.3
-633.15
-342.06
-291.94
-381.48
- -
Working Capital
126
249
224
228
142
221
490
565
766
724
LT Debt
- -
- -
35
24
13
61
68
62
56
52
Total Equity
137
273
294
343
263
334
596
685
865
819
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-19.74
-35.59
-34.25
-28.49
-30.54
-18.08
-14.53
-14.82
- -

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
6
6
6
LT Borrowings
- -
- -
- -
LT Finance Leases
56
54
52
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
64
64
64
Market Capitalization
5,702
5,027
5,059

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
787
765
744
Cash, Cash Equivalents & STI
752
727
710
Accounts Receivable, Net
3
2
2
Inventories
8
9
8
Total Current Liabilities
21
19
20
Payables & Accruals
- -
- -
- -
ST Debt
6
6
6
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
24.67%
26.41%
Free Cash Flow
- -
-4.03%
44.35%
Net Income, GAAP
- -
2.19%
23.38%
Sales/Revenue/Turnover
- -
55.26%
-5.58%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3
4
15
11
32
2025
10
9
- -
6
30
2026
6
5
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.57
-0.45
-0.23
-0.38
-1.62
2025
-0.48
-0.52
- -
-0.47
-1.89
2026
-0.36
-0.39
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chia Chu Tsai
Full Time Employees
27
Sector
Health technology
Industry
Biotechnology
Address
No. 13-20, Minquan East Road Taipei TP Taiwan 11494
IPO Date
May 21, 2024
Website
unicocell.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
UnicoCell Biomed Co., Ltd. (6794.TW) develops stem cell therapies and regenerative medicine solutions focused on adipose-derived mesenchymal stem cells. The company offers ELIXCYTE, an allogeneic stem cell product in Phase 2 clinical trials for knee osteoarthritis and chronic kidney disease; stem cell secretome and high-concentration exosome products for skin care, hair restoration, and therapeutic applications; autologous stem cell therapy for burns and wound healing; an allogeneic adipose stem cell bank serving clinical trials and research; and customized CDMO services for cell therapy production from its PIC/S GMP-certified pilot plant. UnicoCell Biomed operates primarily in Taiwan with exports to Japan and expansion into South Korea; it is headquartered in Taipei and was incorporated in 2018 as a spin-off from DV BioMed group founded in 2011. Recent developments include receipt of US FDA Fast Track Designation for ELIXCYTE in chronic kidney disease in March 2025; approval from Taiwan's Ministry of Health and Welfare for extension of its Human Organ Bank license and PIC/S GMP pilot plant certification in March 2025; transfer of stock listing to the Taiwan Stock Exchange General Board in July 2025; a strategic partnership with New Cell Bio in August 2025 to enter the South Korean regenerative medicine market with stem cell and exosome products; and a domestic alliance with Mentor Group, Taiwan's largest hair salon chain, for exosome-based hair care in February 2025.